Pokud jste položku nepřidali do nákupního košíku nebo do oblíbených, vaše konfigurace se při zavření neuloží.
Chcete-li zavřít nástroj MILLIPLEX® MAP, klikněte na OK. Pokud se chcete vrátit ke svým výběrům, klikněte na Zrušit.
Vyberte přizpůsobitelné panely a soupravy smíchané předem – NEBO - soupravy buněčné signalizace MAPmates™
Navrhněte si a oceňte své soupravy MILLIPLEX® MAP.
Přizpůsobitelné panely a soupravy smíchané předem
Naše široké portfolio se skládá z multiplexních panelů, které vám umožňují vybrat v rámci panelu analyty přesně podle vašich představ. Na zvláštní kartě si můžete zvolit formát předem smíchaných cytokinů, nebo soupravu single plex.
Soupravy buněčné signalizace a MAPmates™
Vyberte pevné soupravy, které vám umožní prozkoumat celé cesty nebo procesy. Nebo si sestavte své vlastní soupravy ze single plex MAPmates™, při dodržení uvedených pokynů.
Následující MAPmates™ by se neměly spolu mísit: -MAPmates™ vyžadující jiný testovací pufr -Fosfo-specifické a celkové páry MAPmate™, např. celkové GSK3β a GSK3β (Ser 9) -PanTyr a MAPmates™ specifické pro lokalitu, např. receptor fosfo-EGF a fosfo-STAT1 (Tyr701) -Více než 1 fosfo-MAPmate™ pro jediný cíl (Akt, STAT3) -GAPDH a β-Tubulin nelze mísit se soupravami nebo MAPmates™ obsahujícími panTyr
.
Katalogové číslo
Popis objednávky
ks/bal.
Seznam
Položka byla přidána do oblíbených.
Vyberte druh, typ panelu, soupravu nebo typ vzorku
Chcete-li začít s návrhem vaší soupravy MILLIPLEX® MAP, vyberte příslušný druh, typ panelu nebo soupravu.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Položka byla přidána do oblíbených.
Druh
Typ panelu
Vybraná souprava
ks
Katalogové číslo
Popis objednávky
ks/bal.
Cena podle ceníku
96-Well Plate
ks
Katalogové číslo
Popis objednávky
ks/bal.
Cena podle ceníku
Přidat další reagencie (Pro použití s MAPmates jsou vyžadovány pufr a detekční souprava)
ks
Katalogové číslo
Popis objednávky
ks/bal.
Cena podle ceníku
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Možnost úspory místa Zákazníci, kteří si pořizují různé soupravy, se mohou rozhodnout pro úsporu místa tím, že nevyžadují balení soupravy a zboží si nechají dodat ve formě multiplexních komponent testů v plastových sáčcích, které se pak kompaktněji skladují.
Položka byla přidána do oblíbených.
Produkt byl přidán do vašeho nákupního košíku
Nyní můžete upravit další soupravu, vybrat předem smíchanou soupravu, odhlásit se nebo zavřít objednací nástroj.
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More
CI-994 or N-acetyldinaline [4-(acetylamino)-N-(2-amino-phenyl) benzamide] is an antitumor cytostatic agent currently undergoing clinical trial. Although several changes in cellular metabolism induced by the drug have been characterized, the primary molecular mechanism of its antitumor activity has been previously unknown. Here, we show that CI-994 is a histone deacetylase (HDAC) inhibitor that causes histone hyperacetylation in living cells. In assays of isolated enzymes, CI-994 inhibited HDAC-1 and HDAC-2 in a concentration-dependent fashion but had no effect on the activity of the prototypical histone acetyltransferase GCN5. Acetylated histone H3-specific Western blots were used to monitor histone acetylation in HCT-8 colon carcinoma cells treated with CI-994 in vitro. CI-994 induced hyperacetylation of H3 in a time- and dose-dependent fashion. H3 hyperacetylation was detectable as early as 30 min after the addition of CI-994 to cells. These data demonstrate that inhibition of HDAC is an early event in cells treated with CI-994 and suggest that this inhibition is mechanistically related to the antitumor activity of this compound.
This study was done to determine whether alpha -phenyl-N-tert-butylnitrone (PBN), a spin-trapping agent possessing significant anti-inflammatory capabilities, could attenuate hyperoxia-induced lung injury, and if so, whether this protective effect is mediated by the down-modulation of inflammation in neonatal rats. Newborn Sprague-Dawley rat pups were subjected to 14 days of hyperoxia (> 90% oxygen) within 10 hours after birth. PBN treatment, given 100 mg/kg intraperitoneally daily throughout the experiment, significantly attenuated hyperoxia-induced lung pathology, such as decreased radial alveolar count, increased mean linear intercept, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling-positive cells. Hyperoxia-induced activation of nicotinamide adenine dinucleotide phosphate oxidase that is responsible for superoxide anion production, as evidenced by up-regulation and membrane translocation of p67phox, and the inflammatory responses, such as increased mRNA expression of tumor necrosis factor-alpha, interleukin-6, and transforming growth factor-beta, were also significantly attenuated with PBN treatment. In summary, a spin-trapping agent PBN significantly attenuated hyperoxia-induced lung injury by down-regulating the inflammatory responses in neonatal rats.
Typ dokumentu:
Reference
Katalogové číslo produktu:
S7110
Název katalogu produktů:
ApopTag® Fluorescein In Situ Apoptosis Detection Kit
We assessed the presence of degenerating neurons in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) of parkinsonian monkeys. For this purpose, we used two histological markers of cellular death, Fluoro Jade B (FJB) staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL). Eight monkeys were subacutelly treated with four to six 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injections (1-1.5 mg/kg, cumulative dose) and sacrificed 1 week and 11 months after last MPTP injection. Eight additional monkeys were chronically exposed to MPTP (4.5-15.3 mg/kg, cumulative dose) and sacrificed 6-35 months after last MPTP dose. Three intact monkeys served as controls. The number of tyrosine hydroxylase (TH)- and TUNEL-positive cells was quantified in SNpc and VTA and colocalization of FJB-positive and TUNEL-positive cells with neuronal (TH, NeuN, MAP2) and glial markers (human ferritin, GFAP) assessed on doubly labelled tissue sections. Only MPTP monkeys with 1-week survival displayed few doubly FJB-TH-labelled cells. Both groups of subacute MPTP monkeys, but not chronic MPTP monkeys, showed a significant increased number of TUNEL-positive cells in SNpc. TUNEL-positive cells exhibited morphological features and histological markers indicative of glial cells, whereas TUNEL/NeuN or TUNEL/MAP-2 colocalization was not observed. Our results indicate that MPTP treatment produced a nonapoptotic cell death of dopaminergic cells and the activation of the apoptotic cascade in glial cells. More importantly, we failed to demonstrate the existence of a delayed neurodegenerative process in the dopaminergic neurons after concluding MPTP injection thus, casting doubt on the validity of the "progressive model" created by repeated MPTP administration to monkeys.
Sirtuins are NAD-dependent protein deacetylases that were shown to have beneficial effects against age-related diseases. SIRT2 is a strong deacetylase that is highly expressed in brain. It has been associated with neurodegenerative diseases. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a dopaminergic neurotoxin that replicates most of the clinical features of Parkinson disease (PD) and produces a reliable and reproducible lesion of the nigrostriatal dopaminergic pathway and neurodegeneration after its systemic administration. Chronic administration of MPTP induces lesion via apoptosis. We show here that SIRT2 deacetylates Foxo3a, increases RNA and protein levels of Bim, and as a result, enhances apoptosis in the MPTP model of PD. We also show that neurodegeneration induced by chronic MPTP regimen is prevented by genetic deletion of SIRT2 in mouse. Deletion of SIRT2 leads to the reduction of apoptosis due to an increase in acetylation of Foxo3a and a decrease in Bim levels. We demonstrate that SIRT2 deacetylates Foxo3a, activates Bim, and induces apoptosis only in 1-methyl-4-phenylpyridinium-treated cells. Therefore, designing SIRT2 inhibitors might be helpful to develop effective treatments for PD.
Many studies have shown that deficits in olfactory and cognitive functions precede the classical motor symptoms seen in Parkinson's disease (PD) and that olfactory testing may contribute to the early diagnosis of this disorder. Although the primary cause of PD is still unknown, epidemiological studies have revealed that its incidence is increased in consequence of exposure to certain environmental toxins. In this study, most of the impairments presented by C57BL/6 mice infused with a single intranasal (i.n.) administration of the proneurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1 mg/nostril) were similar to those observed during the early phase of PD, when a moderate loss of nigral dopamine neurons results in olfactory and memory deficits with no major motor impairments. Such infusion decreased the levels of the enzyme tyrosine hydroxylase in the olfactory bulb, striatum, and substantia nigra by means of apoptotic mechanisms, reducing dopamine concentration in different brain structures such as olfactory bulb, striatum, and prefrontal cortex, but not in the hippocampus. These findings reinforce the notion that the olfactory system represents a particularly sensitive route for the transport of neurotoxins into the central nervous system that may be related to the etiology of PD. These results also provide new insights in experimental models of PD, indicating that the i.n. administration of MPTP represents a valuable mouse model for the study of the early stages of PD and for testing new therapeutic strategies to restore sensorial and cognitive processes in PD.